| 000 | 01706 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515202926.0 | ||
| 264 | 0 | _c20101015 | |
| 008 | 201010s 0 0 eng d | ||
| 022 | _a1365-2141 | ||
| 024 | 7 |
_a10.1111/j.1365-2141.2009.08061.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aScott, Bart L | |
| 245 | 0 | 0 |
_aProlonged responses in patients with MDS and CMML treated with azacitidine and etanercept. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _cMar 2010 |
||
| 300 |
_a944-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aAzacitidine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myelomonocytic, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xadministration & dosage |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRamakrishnan, Aravind | |
| 700 | 1 | _aStorer, Barry | |
| 700 | 1 | _aBecker, Pamela S | |
| 700 | 1 | _aPetersdorf, Steve | |
| 700 | 1 | _aEstey, Elihu H | |
| 700 | 1 | _aDeeg, H Joachim | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 148 _gno. 6 _gp. 944-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2141.2009.08061.x _zAvailable from publisher's website |
| 999 |
_c19442719 _d19442719 |
||